drugset / Trial / NCT04245371

Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

NCT04245371 ↗

Phase 4 Completed 45 enrolled John Papakonstantinou, MD Scilex Ltd. · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective is to determine the efficacy of Lidocaine Patch 1.8% in reducing the severity of symptoms in participants with moderate-to-severe pain from Carpal Tunnel Syndrome.

Timeline

Start
2020-02-24
Primary completion
2023-05-07
Completion
2023-05-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 1.8 % Topical